Aurobindo Pharma Limited reported a 5.6% year-on-year increase in consolidated revenue from operations to Rs. 8,853 crore for Q4 FY26, driven by broad-based growth across business segments, particularly Europe and Growth Markets. 

Net profit for the quarter rose 2% YoY to Rs. 921 crore. 

The company’s Europe business emerged as a standout performer, recording a 30.2% YoY rise in quarterly revenues to Rs.  2,795 crore (EUR 261 million), helping the region cross the €1 billion annual revenue milestone in FY26. 

Growth Markets revenues increased 24.7% YoY to Rs. 980 crore, while ARV revenues grew 6.4% to Rs. 328 crore. 

However, the US formulations business declined 13% YoY to Rs. 3,543 crore due to lower transient sales, though it still contributed 40% of consolidated revenues during the quarter. 

For the full financial year FY26, consolidated revenue from operations increased 6.1% to Rs. 33,653 crore, while annual net profit stood at Rs. 3,503 crore. EBITDA before R&D came in at Rs.  8,340 crore with a margin of 24.8%. 

R&D spend, including depreciation, stood at Rs. 400 crore during the quarter, accounting for 4.5% of revenues. The company also received final approval for nine ANDAs from the USFDA during Q4 FY26 and launched 12 products in the US market. 

K. Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, said the company’s performance reflected the resilience of its business model, strong product portfolio, improved operational efficiencies, and disciplined execution.